Results 281 to 290 of about 125,716 (297)

Current and Emerging Issues in Familial Hypobetalipoproteinemia-related Steatotic Liver Diseases. [PDF]

J Clin Transl Hepatol
Lou TW, Ren TY, Fan JG.
europepmc   +1 more source

Metabolic-Associated Steatotic Liver Disease and FGF21 Dysregulation in Seipin-Deficient and <i>BSCL2</i>-Associated Celia's Encephalopathy Murine Models. [PDF]

Int J Mol Sci
Cobelo-Gómez S, García-Formoso L, Fernández-Pombo A, Lázare-Iglesias H, Díaz-López E, Prado-Moraña T, Rodríguez-Sobrino L, Senra A, Araújo-Vilar D, Sánchez-Iglesias S.   +9 more
europepmc   +1 more source

Chronic-plus-binge alcohol intake induces production of proinflammatory mtDNA-enriched extracellular vesicles and steatohepatitis via ASK1/p38MAPKα-dependent mechanisms. [PDF]

JCI Insight
Ma J, Cao H, Rodrigues RM, Xu M, Ren T, He Y, Hwang S, Feng D, Ren R, Yang P, Liangpunsakul S, Sun J, Gao B.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nonalcoholic Steatohepatitis: A Review.

Journal of the American Medical Association (JAMA), 2020
Importance Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression, development of cirrhosis, and need for liver transplant.
A. Sheka, O. Adeyi, Julie Thompson, B. Hameed, P. Crawford, S. Ikramuddin   +5 more
semanticscholar   +1 more source

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

New England Journal of Medicine
BACKGROUND Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Arun J. Sanyal, Philip N Newsome, Iris Kliers, L. Østergaard, Michelle T. Long, M. Kjær, Anna M G Cali, Elisabetta Bugianesi, M. Rinella, Michael Roden, Vlad Ratziu   +10 more
semanticscholar   +1 more source

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

New England Journal of Medicine
BACKGROUND Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death.
Rohit Loomba, M. Hartman, E. Lawitz, R. Vuppalanchi, Jérôme Boursier, E. Bugianesi, Masato Yoneda, C. Behling, O. Cummings, Yuanyuan Tang, B. Brouwers, Deborah A. Robins, A. Nikooie, Mathijs C Bunck, Axel Haupt, Arun J. Sanyal   +15 more
semanticscholar   +1 more source

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial

Alimentary Pharmacology and Therapeutics
Semaglutide, a glucagon‐like peptide‐1 receptor agonist, has demonstrated potential beneficial effects in metabolic dysfunction‐associated steatohepatitis (MASH).
Philip N. Newsome, Arun J. Sanyal, Kristiane A. Engebretsen, Iris Kliers, L. Østergaard, Denise Vanni, Elisabetta Bugianesi, M. Rinella, M. Roden, V. Ratziu   +9 more
semanticscholar   +1 more source